Physician profile

Laura Reed

Primary Care · Memphis, TN

NPI 1881719938

$1,479.57

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$166.16

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Shield Therapeutics INC $480.00 2022
Abbott Laboratories $308.52 2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $170.63 2021-2022
Teva Pharmaceuticals USA, INC. $125.00 2021
Bayer Healthcare Pharmaceuticals INC. $116.59 2022
Xeris Pharmaceuticals, INC. $112.67 2022
Novo Nordisk INC $91.69 2023
Biogen, INC. $28.80 2023
Ortho-Clinical Diagnostics, INC. $27.37 2024 Vitros
Medtronic, INC. $18.30 2023 Truclear

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Laura Reed

$1,479.57

in general payments reported 2019-2025

Years
2021-2024
Top company
Shield Therapeutics INC

https://glasscript.com/doctor/11160040/laura-reed

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.